Evidence map›Paper›PMID 41425906›Full record

ArticleMass gathering medicine (Amsterdam, Netherlands)2025

Implementation of GLASS-AMR: An assessment in WHO's Eastern Mediterranean Region.

Mohamed Sarhan, Shaffi Fazaludeen Koya, Elizabeth Tayler, Hala Amer, Benedetta Allegranzi, Yvan Hutin

Abstract read
In one paragraph

Article in Mass gathering medicine (Amsterdam, Netherlands), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mohamed SarhanWorld Health Organization Regional Office for the Eastern Mediterranean, Cairo, Egypt.
Shaffi Fazaludeen KoyaWorld Health Organization Regional Office for the Eastern Mediterranean, Cairo, Egypt.
Elizabeth TaylerAntibiotic Policy Unit, City St George's University, London, UK.
Hala AmerWorld Health Organization Regional Office for the Eastern Mediterranean, Cairo, Egypt.
Benedetta AllegranziWorld Health Organization Regional Office for the Eastern Mediterranean, Cairo, Egypt.
Yvan HutinWorld Health Organization Regional Office for the Eastern Mediterranean, Cairo, Egypt.

Funding

World Health Organization 001
6 · The paper itself

Abstract

Background: Global Antimicrobial Resistance and Use Surveillance System-antimicrobial resistance (GLASS AMR) aimed to create national surveillance systems to estimate the extent and burden of AMR globally. Methods: We adapted the United States Centers for Disease Control framework to evaluate GLASS-AMR implementation in WHO's Eastern Mediterranean Region by (1) describing the system and (2) reviewing its key attributes using mixed methods. We reviewed GLASS documents, reports, manuals, Regional External Quality Assessment Scheme (REQAS) survey and progress reports submitted by WHO technical consultants over the years, analyzed the surveillance data generated in the Region and finally triangulated the key findings with selected national focal points from ministries of health. Results: All countries submitted to the GLASS at least once by 2022. Representativeness varied between countries, and the data management and reporting requirements were quite complex due to differences in the laboratory record keeping and data information systems. Patient selection process and insufficient laboratory quality assurance measures might have affected the sensitivity and quality of the data. Although in some respects the quality of data was better compared to other WHO Regions, there is substantial variation in quality and data completeness between countries within the Region. In terms of timeliness, the design of the system based on yearly reports meant that local feedback loops that would have guided timely local decision making did not always happen. GLASS demonstrated to be flexible with inclusion of new pathogens and specimen types. Conclusion: Variable level of quality across countries, and issues of sensitivity, representativeness, and timeliness issues might have affected the usefulness of the system to guide decision making. Implementing national AMR surveillance systems should focus on sustainability and generating and using good quality data for timely action.

Indexed as

Antimicrobial resistanceData qualitySurveillanceWHO GLASS

Identifiers

PMID41425906
PMCPMC12713532

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.